{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002091","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.329427+00:00","generated_at":"2026-06-20T18:26:49.078009+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Regeneron: FY2022 EYLEA US sales $6.26B (+8%), Q4 $1.50B (-3%); expects $30M IPR&D charge","bullets":["FY2022 EYLEA US net product sales ~$6.26B (+8% YoY); Q4 2022 ~$1.50B (-3% YoY).","Q4 EYLEA negatively impacted by short-term shift to off-label compounded Avastin and temporary closure of co-pay assistance fund; reversal beginning per Dec 2022 market data.","Expects ~$30M IPR&D charge from CytomX collaboration, reducing Q4 2022 GAAP/non-GAAP diluted EPS by ~$0.21.","Aflibercept 8 mg BLA submitted for wAMD and DME using priority review voucher; potential FDA approval by late August 2023.","Dupixent approved in 2022 for AD infants (6mo-5yr), EoE, prurigo nodularis; sBLA submitted for CSU in biologic-naïve patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002091","json":"https://secwatch.observer/filing/0001104659-23-002091.json","markdown":"https://secwatch.observer/filing/0001104659-23-002091.md","text":"https://secwatch.observer/filing/0001104659-23-002091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465923002091/0001104659-23-002091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465923002091/tm231703d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:26:49.078009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d3793f40a1c16f8f26a346a9e8808cb6635263f","claim":"REGENERON PHARMACEUTICALS, INC. reported full year 2022 results: revenue approximately $6.26 billion.","evidence_excerpt":"The presentation includes information regarding the Company’s preliminary (unaudited) U.S. net product sales of EYLEA ® (aflibercept) Injection of approximately $6.26 billion for the full year 2022 (based on preliminary (unaudited) fourth quarter 2022 U.S. net product sales of EYLEA of approximately $1.50 billion).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923002091/0001104659-23-002091-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"approximately $6.26 billion"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}